96
Ligumsky M, Lysy J, Siguencia G, Friedlander Y (2001) Effect of long-term, continuous versus
alternate-day omeprazole therapy on serum gastrin in patients treated for reflux esophagitis.
J Clin Gastroenterol 33(1):32–35
Liu L, Ding W, Zhao F, Shi L, Pang Y, Tang C (2013) Plasma levels and potential roles of catestatin
in patients with coronary heart disease. Scand Cardiovasc J: SCJ 47(4):217–224. doi:10.3109
/14017431.2013.794951
Loh YP, Cheng Y, Mahata SK, Corti A, Tota B (2012) Chromogranin A and derived peptides in
health and disease. Journal of Molecular Neuroscience: MN 48(2):347–356. doi:10.1007/
s12031-012-9728-2
Lugardon K, Raffner R, Goumon Y, Corti A, Delmas A, Bulet P, Aunis D, Metz-Boutigue MH
(2000) Antibacterial and antifungal activities of vasostatin-1, the N-terminal fragment of chro-
mogranin A. J Biol Chem 275:10745–10753
Maestroni S, Maestroni A, Ceglia S, Tremolada G, Mancino M, Sacchi A, Lattanzio R, Zucchiatti
I, Corti A, Bandello F, Zerbini G (2015) Effect of chromogranin A-derived vasostatin-1 on
laser-induced choroidal neovascularization in the mouse. Acta Ophthalmol 93(3):e218–e222.
doi:10.1111/aos.12557
Mahata SK, Mahata M, Fung MM, O'Connor DT (2010) Catestatin: a multifunctional peptide
from chromogranin A. Regul Pept 162(1–3):33–43
Mandalà M, Stridsberg M, Helle KB, Serck-Hanssen G (2000) Endothelial handling of chromo-
granin A. Adv Exp Med Biol 482:167–178
Marcucci F, Corti A (2011) How to improve exposure of tumor cells to drugs – promoter drugs
increase tumor uptake and penetration of effector drugs. Adv Drug Deliv Rev. doi:10.1016/j.
addr.2011.09.007
Marcucci F, Corti A (2012) Improving drug penetration to curb tumor drug resistance. Drug
Discov Today 17(19–20):1139–1146. doi:10.1016/j.drudis.2012.06.004
Mehta D, Malik AB (2006) Signaling mechanisms regulating endothelial permeability. Physiol
Rev 86(1):279–367. doi:10.1152/physrev.00012.2005
Meng L, Wang J, Ding WH, Han P, Yang Y, Qi LT, Zhang BW (2013) Plasma catestatin level
in patients with acute myocardial infarction and its correlation with ventricular remodelling.
Postgrad Med J 89(1050):193–196. doi:10.1136/postgradmedj-2012-131060
Metz-Boutigue MH, Garcia-Sablone P, Hogue-Angeletti R, Aunis D (1993) Intracellular and
extracellular processing of chromogranin A. Determination of cleavage sites. Eur J Biochem
217(1):247–257
Montesinos MS, Machado JD, Camacho M, Diaz J, Morales YG, Alvarez de la Rosa D, Carmona
E, Castaneyra A, Viveros OH, O'Connor DT, Mahata SK, Borges R (2008) The crucial role of
chromogranins in storage and exocytosis revealed using chromaffin cells from chromogranin A
null mouse. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience
28(13):3350–3358. doi:10.1523/JNEUROSCI.5292-07.2008
Mosley CA, Taupenot L, Biswas N, Taulane JP, Olson NH, Vaingankar SM, Wen G, Schork NJ,
Ziegler MG, Mahata SK, O'Connor DT (2007) Biogenesis of the secretory granule: chromo-
granin A coiled-coil structure results in unusual physical properties and suggests a mechanism
for granule core condensation. Biochemistry 46(38):10999–11012
O’Connor DT, Bernstein KN (1984) Radioimmunoassay of chromogranin A in plasma as a mea-
sure of exocytotic sympathoadrenal activity in normal subjects and patients with pheochromo-
cytoma. N Engl J Med 311(12):764–770
O’Connor DT, Deftos LJ (1986) Secretion of chromogranin A by peptide-producing endocrine
neoplasms. N Engl J Med 314(18):1145–1151
O’Connor DT, Mahata SK, Taupenot L, Mahata M, Livsey Taylor CV, Kailasam MT, Ziegler MG,
Parmer RJ (2000) Chromogranin A in human disease. Adv Exp Med Biol 482:377–388
O’Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ (2002) Early
decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of
hypertension. J Hypertens 20(7):1335–1345
F. Curnis et al.